FBR Capital says it views the data from a metastatic cervical cancer study conducted by the National Cancer Institute published in the Journal of Clinical Oncology as positive for Lion Biotechnologies. FBR notes data from the trial showed objective responses in patients after a single infusion of Lion's human papillomavirus tumor-infiltrating lymphocytes. The firm believes use of Lion's TILs therapy for indications outside of metastatic melanoma could eventually provide the company with a "significant" opportunity. It has an Outperform rating on the stock.